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Overdose of acetaminophen (APAP) is the leading cause of acute liver failure (ALF). 
Although mechanisms of APAP-induced liver injury are well known, those that affect the 
progression of APAP-induced liver disease and facilitate liver recovery are less understood. The 
sulfotransferase 2B1b (SULT2B1b) participates various of liver relative diseases including 
metabolic syndrome, chronic liver injury and hepatocellular carcinoma. Our previous study 
showed that SULT2B1b is transcriptional regulated by Hepatic Nuclear Factor 4α (HNF4α), which 
is essential for liver development and function. However, the importance of SULT2B1b in APAP-
induced acute liver injury remains unknown. In this study, we examined the role of SULT2B1b in 
APAP-induced hepatotoxicity. We showed that hepatic overexpression of SULT2B1b in liver 
sensitized mice to APAP-induced liver injury, whereas ablation of Sult2B1b conferred resistance 
to the APAP hepatotoxicity. Indeed, upregulation of Sult2B1b by Hnf4α in wild type mice showed 
more severe liver injury and this effect was abolished in Sult2B1b knockout mice evidenced by 
comparable liver damage. Therefore, we conclude that SULT2B1b represents a potential 
therapeutic target for the prevention and treatment of APAP-induced acute liver injury. 
The Role of Sulfotransferase 2B1b in Acetaminophen-induced Liver Injury 
Yunqi An, B.S 
University of Pittsburgh, 2018
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1.0  INTRODUCTION 
 
1.1 ACETAMINOPHEN IN LIVER INJURY 
1.1.1 Epidemiology 
Drug-induced liver injury (DLI) and acute liver failure (ALF) remains a major problem in Western 
societies. Among different etiologies, acetaminophen (APAP) is the leading cause of ALF1,2. An 
epidemiological study suggests that among 308 consecutive patients with liver failure admitted to 
1 of 17 referral centers in the United States between 1998 and 2001, 39% are due to APAP 
overdose3. APAP is a widely and commonly used drug to relieve pain and reduce fever. As early 
as 1955, APAP was first introduced for prescription4. By 1960s, reports appear that APAP is 
associated with liver injury5. In the United States, around 50 million people use APAP or APAP-
combination products each week6. In 2014, the American Association of Poison Control Centers' 
National Poison Data System reported 67,187 adult and pediatric cases involving APAP alone and 
47,588 cases involving APAP in combination with other drugs. There were 996 cases of major 
APAP toxicity (defined as life threatening or disabling) and 108 cases of APAP-related deaths7. 
Therefore, liver injury resulting from unintentional APAP overdose becomes an urgently issue that 
must be solved.  
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1.1.2 APAP metabolism 
The initial phases of APAP toxicity were described in Dr. Gillette’s laboratory in the 1970s8. At 
therapeutic doses, about 3% of APAP is excreted as prototype via urine. More than 90% of APAP 
can be rapidly metabolized by Phase II conjugating enzymes, two thirds through glucuronidation 
by UDP-glucuronosyltransferases (UGTs) and one third through sulfation by sulfotransferases 
(SULTs) to the nontoxic compounds which are mainly excreted in the urine and bile. There is also 
5%-9% of APAP undergoes another bioactivation pathway by Phase I cytochrome P450 enzymes 
(CYPs), especially CYP2E1, to the highly reactive toxic intermediate metabolite, N-acetyl-p-
benzoquinone imine (NAPQI)9,10. It has a short half-life and is rapidly eliminated by conjugation 
with glutathione (GSH)11. Then it is excreted via urine as mercapturic acid and cysteine conjugates.  
1.1.3 APAP hepatotoxicity 
APAP hepatotoxicity is directly related to the dose. At doses of more than 4 g/day, can lead to 
serious hepatotoxicity. In the event of APAP overdose, the glucuronidation and sulfation pathways 
are saturated so more amount of APAP is metabolized by CYPs to NAPQI. Excessive NAPQI 
depletes intracellular GSH. As a result, accumulated NAPQI will bind to cellular proteins and lead 
to hepatocyte death11,12.  
The degree of hepatic toxicity correlates with GSH availability. GSH depletion contributes 
to cellular oxidant stress. NAPQI will bind to critical cellular targets, such as mitochondrial 
proteins. The ultimate result is alteration in calcium homeostasis, mitochondrial dysfunction with 
ATP depletion, DNA damage, and intracellular protein modification. These events lead to necrotic 
cell death13,14. 
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There are a bunch of factors influencing APAP hepatotoxicity. First of all, the metabolism 
of APAP depends on age. Children and infants seem to be less susceptible to APAP 
hepatotoxicity15. Since hepatic toxicity is also relative to the activity of the catalyzing enzyme 
systems, polymorphisms in CYPs play an important role in APAP metabolism and toxicity16. 
Interestingly, people suffered chronic liver injury are no more sensitive to APAP-induced acute 
liver injury due to liver regeneration17,18. Fasting may also enhance APAP toxicity. It is probably 
because of GSH depletion and CYP2E1 induction during fasting19. Alcohol has an effect on APAP 
hepatotoxicity but it depends on acute or chronic alcohol intake. Acute intake may protect because 
alcohol competes with APAP for CYPs. But it is different in chronic alcohol intake. CYP2E1 is 
induced and GSH is depleted by alcohol14,19. All of these factors are involved in APAP 
hepatotoxicity and play important roles. 
1.1.4 Treatment approaches for APAP overdose 
The main goal of treatment is to prevent or minimize liver injury following APAP overdose. N-
acetylcysteine (NAC), a clinical antidote for APAP overdose, is nearly 100% hepatoprotective 
when it is given within 8 hours after an acute APAP overdose14,20. However, NAC has a narrow 
therapeutic window21. NAC may be given orally or intravenously. Although the oral route is 
simpler, it frequently causes nausea and vomiting and is unpleasant. Additionally, the standard 
oral regime is 72 hours in duration as compared with about 20 hours intravenously, although this 
is somewhat arbitrary22. Many centers now shorten the duration of oral use by monitoring the 
serum APAP level and liver enzyme levels. The intravenous route is generally well tolerated, 
although there is a significant incidence of anaphylactoid reactions. There is no evidence of 
difference in efficacy between the two routes. NAC also has some therapeutic effect for patients 
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who present 10 to 24 hours after ingestion, although its efficacy diminishes as the time to treatment 
increases. Intravenous NAC may be of benefit when rendered as late as 36 to 80 hours in 
patients23,24. 
In situations where NAC is not available, oral methionine may be an alternative option. 
Under such rare circumstances where there is no antidotal therapy available, oral-gastric lavage 
and activated charcoal should be considered given the morbidity and mortality from APAP toxicity 
in the absence of antidotal therapy. If no other options are available, hemodialysis may be 
considered as a means of rapidly decreasing the serum APAP concentration in patients presenting 
soon after an acute APAP overdose, provided hemodialysis can be expeditiously initiated and its 
benefits outweigh its risks25,26. 
1.2 SULFOTRANFERASE 2B1b IN APAP-INDUCED LIVER INJURY 
1.2.1 Cytosolic SULT family 
The human cytosolic SULT family consists of encoding 14 different isoforms. The human SULT2 
family, also called hydroxysteroid-SULT family, consists of only 2 genes, termed SULT2A1 and 
SULT2B1. The SULT2 enzymes sulfate a variety of substrates, such as DHEA, pregnenolone and 
cholesterol27. However, they show different tissue distribution, specificities and activities. Based 
on the length of transcripts, SULT2B1 termed SULT2B1a and SULT2B1b. In transcriptional level, 
SULT2B1a and SULT2B1b are highly similar. But only SULT2B1b protein can be detected by 
immunoblot in human28. Therefore, SULT2B1a message may not be efficiently translated in 
human tissues. SULT2B1b has been identified by immunoblot in prostate29, placenta30, intestine31, 
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breast32, skin33 and platelets34. SULT2B1b appears to be the major active SULT2B1 isoform in 
human tissues. SULT2B1b is selective for the sulfation of 3 -hydroxysteroids and also has activity 
with cholesterol suggesting it may have different enzymatic functions in different human tissues27.  
1.2.2 SULT2B1b in liver diseases 
Previous studies have suggested a critical role of SULT2B1b in regulating the chemical and 
functional homeostasis of endogenous and exogenous molecules and in a variate of diseases. Based 
on our previous study, SULT2B1b is transcriptional regulated by HNF4α to prevent uncontrolled 
gluconeogenesis35. Although SULT2B1b expression is fairly low in liver, there have been several 
reports indicating that SULT2B1b is crucial in regulation of liver function and diseases. SULT2B1 
is transcriptionally upregulated during liver regeneration in a mouse model of partial 
hepatectomy36. SULT2B1b mRNA levels in clinical hepatocarcinoma tumor samples were higher 
than in the non-tumorous tissue adjacent to the tumors37. Oxysterols, which are considered as 
activators of Liver X Receptor (LXR), are also substrates of SULT2B1b38,39. Upregulation of 
SULT2B1b aggravated 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced liver injury by 
modulating oxysterol-induced LXR activation40. SULT2B1b also can be regulated by nuclear 
receptors, such as CAR41, VDR42 and PPARs43. 
1.3 HNF4Α IN APAP-INDUCED LIVER INJURY 
Hepatocyte Nuclear Factor 4α (HNF4α) is known to modulate regulatory elements in the 
promoters and enhancers of genes involved in cholesterol, fatty acid and glucose metabolism44. 
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Specifically in the liver, HNF4α activates hepatic gluconeogenesis and regulates the expression of 
several genes. A recent study by Lake et al. assessed the role of major transcription factor binding 
sites in non-alcoholic steatohepatitis (NASH)45. HNF4α mRNA expression was significantly 
decreased in human NASH samples, suggesting the contribution of HNF4α to nonalcoholic fatty 
liver disease (NAFLD) development. Using knockout models, previous mouse studies have 
revealed the critical role of HNF4α in the control of bile acid synthesis and glucose homeostasis46,47. 
In addition, an integrative analysis of NAFLD signatures in human and genetically modified 
mouse models demonstrated that HNF4α as a transcription factor plays an important role in 
regulating the expression of the genes involved in the progression of NAFLD to hepatocellular 
carcinoma48.  
In this study, we demonstrated that overexpress SULT2B1b in liver sensitized mice to 
APAP-induced liver injury while deletion of SULT2B1b attenuated its toxicity. Upregulation of 
SULT2B1b by HNF4α aggravated APAP hepatotoxicity and this effect could be abolished in 
SULT2B1b knockout mice. Our study pointed to SULT2B1b as a potential therapeutic target for 
APAP-induced acute liver injury. 
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2.0  METHODS AND MATERIALS 
Animals 
The whole-body Sult2B1b knockout mice (Strain # 018773) and C57BL/6J wild type mice were 
purchased from the Jackson Laboratory (Bar Harbor, ME). FABP-SULT2B1b transgenic mice 
were bred by our laboratory as previously described46. All mice used for the experiments were 6-
8 week-old female mice. All mice were housed under a standard 12-hour light and 12-hour dark 
cycle with free access to food and water. The use of mice in this study complied with all relevant 
federal guidelines and institutional policies.  
Induction of liver injury 
APAP was dissolved in 0.5% methyl cellulose solution. All experiments were performed by fasting 
mice at 4:00 pm and treating APAP to mice by gavage at 8:00 am. Food back 3 hours after 
treatment. The mice were sacrificed 24 hours after APAP treatment49. Liver tissues and serum 
were harvested for biochemical and histological analysis. All chemicals were purchased from 
Sigma (St. Louis, MO). 
Histology 
For H&E staining, tissues were fixed in 10% paraformaldehyde, embedded in paraffin, sectioned 
at 4 mm, and stained with H&E. For immunohistochemistry analysis, standard 
immunohistochemical procedures were performed in detection of Ki67 from Abcam (Cambridge, 
MA). A Novus (Littleton, CO) APO-BRDU (TUNEL) Apoptosis kit was used to examine dying 
cells with exposed or fragmented DNA ends as per the manufacturer's instruction. 
 8 
Serum and liver tissue chemistry 
Levels of ALT and AST in serum50 and cells51 were measured using commercial assay kits from 
Stanbio Laboratory (Boerne, TX). The concentration of GSH in the liver was measured by GSH 
Assay Kit from BioAssay Systems (Hayward, CA). 
Real-time PCR 
Total RNA was isolated using the TRIzol reagent from Invitrogen. Reverse transcription was 
performed with random hexamer primers and Superscript RT III enzyme from Invitrogen. SYBR 
Green-based real-time polymerase chain reaction (PCR) was performed with the ABI 7300 Real-
Time PCR System. The PCR primer sequences are shown in Table 1. The quantity of mRNA was 
normalized to the cyclophilin gene. 
Western blot 
For Western blot analysis, tissues and cells were lysed in ice-cold Nonidet P-40 lysis buffer 
containing a protease inhibitor cocktail from Roche, and then quantified for protein concentrations 
by a bicinchoninic acid assay kit from Pierce. Protein samples were resolved by electrophoresis 
on 10% SDS-polyacrylamide gels. After transfer of proteins to nitrocellulose membranes, the 
membranes were probed with primary antibodies against total AKT (cat. no. 9272) and phospho-
Akt (serine 473) (cat. no. 9271) from Cell Signaling (Beverly, MA). Detection was achieved by 
using the enhanced chemiluminescence system from Amersham (Piscataway, NJ). The signals 
were quantified by using the Image J software (http://imagej.nih.gov/ij/). 
Isolation and culture of primary hepatocytes from mice 
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Primary mouse hepatocytes were isolated from 8 to 12 week-old mice, as previously described. 
Briefly, the liver was first perfused with Hanks’ buffered salt solution containing 0.5 mM EGTA 
and 0.1 M HEPES at 5 ml/min for 5–10 minutes and then perfused with L-15 medium containing 
1.8 mM CaCl2, 0.1 M HEPES, and 20 mg/ml liberase (Roche, Indianapolis, IN). After perfusion, 
the dissociated hepatocytes were filtered through 50-mm pore mesh and collected by 
centrifugation at 500 rpm for 3 minutes at 4°C. Hepatocytes were seeded onto type 1 collagen-
coated dishes in William E medium containing 5% fetal bovine serum. The medium was changed 
to HepatoZYME-SFM medium (GIBCO, Grand Island, NY) 2 hours later. 
Adenovirus transfection 
The primary hepatocytes were treated with adenovirus to overexpress Hnf4α. Adenovirus 
expressing Hnf4α (Ad-Hnf4α) was gift from Dr. Yanqiao Zhang from the Northeast Ohio Medical 
University.  
Statistical analysis 
All the data are expressed as means ± standard error of the mean (SEM). Differences were 
evaluated by the unpaired two-tailed Student’s t test (GraphPad Prism). The criterion for statistical 
significance was a P value of ＜0.05. 
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3.0  RESULTS 
3.1 OVEREXPRESSION OF SULT2B1B IN LIVER AGGRAVATED APAP-
INDUCED LIVER INJURY 
To investigate whether SULT2B1b is indeed important in the pathogenesis of APAP-induced liver 
injury, we first treated SULT2B1b transgenic (TG) mice, which specific overexpress SULT2B1b 
in liver, with a single dose of APAP (200mg/kg, gavage). At 24 hours post-treatment, the tissues 
and serum were harvested to analysis. H&E staining revealed that the SULT2B1b TG mice 
displayed more severe damage compared to wild type (WT) mice. In vehicle-treated mice, no 
significant alteration in liver histology was found in TG mice, when compared to WT mice. But 
after APAP treatment, TG mice showed more typical necrotic liver damage than WT mice. The 
ratio of necrotic area in TG mice is higher than in WT mice as well (Fig. 1A). In addition, APAP-
treated TG mice showed increased serum levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) activity, compared to WT mice (Fig. 1B). The extent of hepatocyte DNA 
fragmentation, as assessed by TUNEL staining, was significantly increased in liver sections from 
TG mice after APAP treatment (Fig. 1C). Liver regeneration is known for survival after APAP 
overdose. Thereby, we also evaluated the proliferation and cell cycle-related gene expressions in 
livers by real-time PCR. TG mice showed significantly higher expression of Pcna than WT mice 
(Fig. 1D). It indicated that TG mice had more liver damage than WT mice. Furthermore, hepatic 
expression of inflammatory cytokines interleukin-6 (Il-6) and interleukin-1β (Il-1β) in TG mice 
was much higher than that in WT mice after APAP treatment. (Fig. 1E). Collectively, 
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overexpression of SULT2B1b results in enhanced liver injury with severe necrosis and increased 
liver regeneration and inflammation. 
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Figure 1. Overexpression of SULT2B1b in liver aggravated APAP-induced liver injury.  
A Representative H&E staining on liver paraffin sections at 24 hours after APAP-treated WT and 
SULT2B1b TG mice (middle, original magnification 100), APAP-induced centrilobular necrosis 
(right panels, enlarged view of boxed region in middle panels) and quantification of necrotic areas 
in liver sections (n=5 per group). B Serum levels of ALT and AST in WT and TG mice treated 
with vehicle or APAP. C Representative images of TUNEL staining in liver sections from WT 
and TG mice at 24 hours after vehicle or APAP treatment (magnification 200). D Relative mRNA 
levels of Pcna, Ki67, C-myc, Ccnd1, and Ccne1 in the livers. E Relative mRNA levels of Il-6, Il-
1β in livers. Data are expressed as mean  SEM. *P < 0.05.  
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3.2 DELETION OF SULT2B1B PROTECTED MICE FROM APAP-INDUCED 
LIVER INJURY 
To assess whether SULT2B1b ablation affects APAP-induced liver injury, we also treated 
Sult2B1b knockout (KO) mice with a single dose of 200mg/kg APAP. As a result, Sult2B1b KO 
mice showed less damage compared to WT mice. The WT liver showed expected typical necrotic 
liver damage at 24 hours post-APAP. In contrast, KO mice showed little signs of damage (Fig. 
2A). Also, APAP-treated KO mice showed reduced serum levels of ALT and AST, compared to 
their WT counterpart (Fig. 2B). In TUNEL staining, KO mice showed significantly less positive 
cells (Fig. 2C). We also evaluated proliferation of hepatocytes by Ki67 staining. KO mice showed 
remarkably less hepatocyte proliferation than WT mice (Fig. 2D). Consistently, mRNA levels of 
Pcna and Ccnd 1 expressions decreased in KO mice as well (Fig. 2E). Moreover, Il-1β mRNA 
expressions were dramatically induced in WT mice than that in KO mice (Fig. 2F). These results 
suggest that deletion of Sult2B1b conferred resistance to APAP hepatotoxicity.  
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Figure 2. Deletion of Sult2B1b protected mice from APAP-induced liver injury. 
A Representative H&E staining on liver paraffin sections at 24 hours after vehicle or APAP-treated 
WT and Sult2B1b KO mice (middle, original magnification 100), APAP-induced centrilobular 
necrosis (right, enlarged view of boxed region in middle panels) and quantification of necrotic 
areas in liver sections (n=2 for WT-vehicle and Sult2B1b KO-vehicle, n=8 for WT-APAP and 
Sult2B1b KO-APAP). B Serum levels of ALT and AST in WT and KO mice treated with vehicle 
or APAP. C Representative images of TUNEL staining in liver sections from WT and Sult2B1b 
KO mice at 24 hours after vehicle or APAP treatment (original magnification 200). D 
Representative images of Ki67 staining in liver sections from WT and Sult2B1b KO mice at 24 
hours after vehicle or APAP treatment (original magnification 200).   E Relative mRNA levels 
of Pcna, Ki67, C-myc, Ccnd1, and Ccne1 in the livers. F Relative mRNA levels of Il-6, Il-1β in 
livers. Data are expressed as mean  SEM. *P < 0.05; **P < 0.01.  
3.3 UPREGULATION OF SULT2B1B BY HNF4Α SENSITIZED MICE TO APAP-
INDUCED LIVER INJURY 
To study the effects of upregulation of SULT2B1b by overexpressing HNF4α on APAP-induced 
acute liver injury, we injected adenovirus to overexpress Hnf4α in WT mice. After a week, these 
mice were treated with APAP as previous experiments. Hnf4α and Sult2B1b protein levels were 
increased compared to control mice (Fig. 3A). Compared to WT mice injected with Ad-Ctrl, WT 
mice injected with Ad-Hnf4α displayed more severe injured liver (Fig. 3B). H&E staining revealed 
more severe and widespread necrosis in WT mice with Ad-Hnf4α compared to control mice (Fig. 
3B). Liver injury was also assessed by ALT and AST levels. After APAP treatment, ALT and AST 
levels were significantly higher in WT mice injected with Ad-Hnf4α than in WT mice injected 
with Ad-Ctrl (Fig. 3C). To further confirm it in vitro, we also isolated primary hepatocytes from 
WT mice and treated them with Ad-Hnf4α. After 5nM APAP treatment for 24 hours, the 
percentage of ALT release slightly increased by Ad-Hnf4α (Fig. 3D). These observations suggest 
that overexpression of HNF4α upregulates SULT2B1b expression and aggravates APAP-induced 
liver injury.   
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Figure 3. Upregulation of Sult2B1b by Hnf4α sensitized mice to APAP-induced liver injury. 
A Hepatic Sult2B1b and Hnf4α expressions in Ad-ctrl+APAP and Ad-Hnf4+APAP WT mice by 
Western blot analysis. B Representative appearance (top) and H&E staining on liver paraffin 
sections of Ad-ctrl+APAP and Ad-Hnf4+APAP WT mice (original magnification 100, middle) 
and APAP-induced centrilobular necrosis (bottom, enlarged view of boxed region in middle 
panels). n=3 for Ad-ctrl+APAP, n=5 for Ad-Hnf4+APAP. C After APAP treatment, serum levels 
of ALT and AST in WT mice injected with Ad-ctrl or Ad-Hnf4α. D Sult2B1b and Hnf4α 
expressions in WT primary hepatocytes treated with Ad-ctrl or Ad-Hnf4α by Western blot analysis. 
E The percentage of ALT release from WT primary hepatocytes treated with 5nM APAP for 24 
hours. Data are expressed as mean  SEM. *P < 0.05.  
 
 
 
3.4 SULT2B1B IS ESSENTIAL FOR THE SENSITIZATION OF HNF4Α IN APAP 
HEPATOTOXICITY 
To understand whether HNF4α sensitizes mice to APAP hepatotoxicity in a SULT2B1b-dependent 
manner, we then injected Ad-Ctrl and Ad-Hnf4α respectively to Sult2B1b KO mice. We first 
verified that Hnf4α was overexpressed in livers of Sult2B1b KO mice (Fig. 4A). After APAP 
treatment, on the contrary, KO mice injected with Ad-Ctrl and Ad-Hnf4α showed similar levels of 
ALT and AST (Fig. 4B). The livers showed comparable damage and the histology is consistent 
with serum analysis as well (Fig. 4C). These findings suggest that deletion of Sult2B1b abolished 
the effect of Hnf4α overexpression on APAP hepatotoxicity. Therefore, we proved that the 
sensitization of HNF4α in APAP-induced liver injury is dependent on SULT2B1b.  
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Figure 4. Sult2B1b is essential for the sensitization of Hnf4α in APAP hepatotoxicity. 
A Hepatic Hnf4α expressions in Ad-ctrl+APAP and Ad-Hnf4+APAP KO mice by Western blot 
analysis. B Representative appearance (top) and H&E staining on liver paraffin sections at APAP-
treated KO mice with Ad-ctrl or Ad-Hnf4α injection (middle, original magnification 100) and 
APAP-induced centrilobular necrosis (bottom, enlarged view of boxed region in middle panels). 
n=3 for Ad-ctrl+APAP, n=5 for Ad-Hnf4+APAP. C After APAP treatment, serum levels of ALT 
and AST in Sult2B1b KO mice injected with Ad-ctrl or Ad-Hnf4α. Data are expressed as mean  
SEM. *P < 0.05.  
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3.5 PROFILE OF APAP METABOLISM IN SULT2B1B TG AND KO MICE 
To pursue the role of SUT2B1b in APAP metabolism, we compared the difference in APAP 
metabolism among these mice in different genotypes. Only Ugt1 was induced in TG mice and the 
expressions of other relative APAP metabolizing enzymes showed no significant difference in both 
TG and KO mice (Fig. 5A). Then the total hepatic GSH content in TG and KO mice was measured 
(Fig. 5B). It was significantly reduced in TG mice but no alterations in KO mice. By LC-MS, the 
concentration of APAP metabolites, APAP-sulfate and APAP-glucuronide, in serum were 
measured (Fig. 5C). Based on current results, it is limited to make a conclusion, so we will also 
measure APAP-cysteine content in liver of these mice.  
 
 
  A 
B 
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Figure 5. Profile of APAP metabolism in SULT2B1b TG and KO mice.  
A Relative mRNA levels of Ugt1, Gstα, Gstμ, Gstπ, Sult2a1 and Cyp2e1 in livers from WT, 
SULT2B1b TG and KO mice treated with APAP. B Total GSH content in livers from WT, 
SULT2B1b TG and KO mice treated with APAP (n=3 per group).  C LC-MS analysis of the 
content of APAP-Sulfate and APAP-Glucuronide in livers from WT, SULT2B1b TG and KO mice 
at 24 hours after APAP treatment. Data are expressed as mean  SEM. *P < 0.05; **P < 0.01.  
 
 
 
C 
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4.0  DISCUSSION 
Identification of the molecular mechanisms during pathogenesis of APAP-induced liver injury will 
provide promising therapeutic avenues for the treatment for APAP overdose. In this study, we first 
demonstrated that the hepatic overexpression of SULT2B1b enhanced APAP-induced acute liver 
injury in mice while ablation of Sult2B1b in mice conferred resistance to this liver injury. 
Furthermore, TG mice also showed increased hepatocyte death and inflammation, whereas KO 
mice reduced. Our previous study showed that SULT2B1b is transcriptionally regulated by 
HNF4α35. Thereby, we also identified that overexpression of Hnf4α to upregulate Sult2B1b 
sensitized WT mice to APAP hepatotoxicity. In contrast, this sensitization of HNF4α was 
abolished in Sult2B1b KO mice. Therefore, Sult2B1b is essential for regulation of HNF4α to 
APAP-induced liver injury.  
SULT2B1b is a hydroxysteriod sulfotransferase which plays an important role in lipid and 
glucose metabolism, inflammatory responses and cell proliferation52,53. It has been reported that 
SULT2B1b is involved in a series of liver diseases, including metabolic syndrome35, HCC37, 
NASH and NAFLD54. Noted that SULT2B1b suppresses LXR activity38,55. We previously 
demonstrated that activation of LXR accelerates APAP clearance to prevent APAP toxicity49. 
Based on these, we are curious about the role of SULT2B1b itself in APAP hepatotoxicity and we 
propose upregulation of SULT2B1b sensitizes mice to APAP-induced liver injury. We followed 
our previous protocol to treat mice with 200mg/kg APAP by gavage after 16-hour fasting49. 
Because fasting accelerates GSH depletion and induces CYP2E1 expression to promote APAP 
toxicity19. As a result, consistent with our hypothesis, TG mice showed significant severe necrosis 
and increased serum ALT and AST levels, whereas KO mice alleviated APAP-induced liver injury 
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and reduced ALT and AST levels. In APAP-induced liver injury, it is believed that overdose of 
APAP is metabolized by CYPs to reactive intermediate NAPQI which depletes GSH, binds to 
cellular proteins and induce nuclear DNA fragmentation, leading to necrotic hepatocyte death13. 
So in this study, we assessed nuclear DNA fragmentation by TUNEL staining. On the other hand, 
hepatocyte necrosis eventually induces liver regeneration56. Liver regeneration is also known to 
be important for survival after APAP overdose57. Usually, more necrosis is followed by more cell 
proliferation. Furthermore, enhanced liver injury in SULT2B1b TG mice was also accompanied 
by an exacerbation of inflammation58, as evidenced by increased hepatic expression of Il-6 or Il-
1β. In contrast, Il-1β decreased in Sult2B1b KO mice. 
HNF4α is a key regulator of both hepatocyte differentiations during embryonic 
development and maintenance of a differentiated phenotype in adult59. It has been shown that 
HNF4α is essential for liver development, lipid and glucose metabolism, NASH, ALF and HCC, 
etc46,48,60,61. Therefore, the regulation of HNF4α and changes in its downstream are essential for 
liver development and function. To overexpress Hnf4α, we tried hydrodynamic transfection and 
adenovirus infection expressing Hnf4α in vivo respectively. By hydrodynamic transfection, 
hepatic expressions of Hnf4α and Sult2B1b rapidly increased at both mRNA and protein levels 
(data not shown). However, hydrodynamic transfection also induce severe liver injury with 
extravasated blood62. We found it is difficult to tell the damage caused by APAP or hydrodynamic. 
And APAP-induced liver damage was compensated probably because of liver regeneration. It is 
probably because of liver regeneration. Therefore, we overexpressed Hnf4α by adenovirus to 
upregulate Sult2B1b. But it takes a week to fully upregulate Sult2B1b so only Hnf4α protein 
increase was detected. Surprisingly, Hnf4α sensitized WT mice to APAP hepatotoxicity. To our 
knowledge, it is the first demonstration proved that HNF4α aggravated APAP-induced liver injury 
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via SULT2B1b upregulation. The mechanism will be illuminated. So SULT2B1b may have a 
directly or indirectly effect on APAP hepatotoxicity. Because adenovirus infection also induced 
mild liver damage leading to liver regeneration, the necrosis after APAP treatment in these mice 
was not as dramatic as simple APAP-treated mice. Then we were wondering whether the 
sensitization of HNF4α is dependent on SULT2B1b. As expected, Sult2B1b KO mice injected 
with Ad-Hnf4α showed similar liver injury to those injected with Ad-ctrl. Thereby, we concluded 
that HNF4α promoted APAP-induced liver injury via SULT2B1b upregulation.  
Our results suggested that most of gene expressions of APAP metabolizing enzymes, 
except for Ugt1 in TG mice, did not change. It indicated that SULT2B1b may be dispensable for 
the metabolism of APAP. But for the total content of GSH, there was an abnormal reduce in TG 
mice. One possible reason is that dramatic necrosis results in GSH degradation.  Because GSH 
depletion reflects the amount of excessive NAPQI, another possible explanation is that 
overexpression of hepatic SULT2B1b affected initial depletion of GSH levels. Further study will 
be needed to elucidate this issue. We preliminarily measured APAP metabolites in serum at 24 
hours post-APAP. To our surprise, two nontoxic metabolites, APAP-sulfate and APAP-
glucuronide, remarkably increased in SULT2B1b TG mice though no significant decrease in KO 
mice. We still need to analyze the concentration of APAP-cysteine in liver to further conclude 
whether SULT2B1b influences APAP metabolism.  
In summary, we have uncovered a novel function of SULT2B1b in APAP-induced acute 
liver injury. Because HNF4α plays a pivotal role in liver development and function, the induction 
of SULT2B1b by HNF4α contributes to an important regulation to APAP hepatotoxicity. Thus, 
our results suggest that hepatic SULT2B1b may be a potential therapeutic target for APAP-induced 
liver injury. 
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